MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202517130940 A) filed by Gmp Biotechnology Limited, Hong Kong, on Dec. 23, 2025, for 'anti-cancer tgfb2 agents with immunotherapeutics.'
Inventor(s) include Trieu, Vuong.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "This invention relates to methods for treating or ameliorating the symptoms of cancer in a human or animal subject with pharmaceutical compositions designed to promote anti-tumor effects. Exemplary synergistic pharmaceutical therapies include compositions having a combination of active agents including agents for inhibiting or suppressing expression of TGF-2, immune checkpoint inhibitor agents, and interleukin immunotherapeutic active agents. One or more biomarkers can be used to select subjects who benefit from the method."
The patent application was internationally filed on June 05, 2024, under International application No.PCT/US2024/032636.
Disclaimer: Curated by HT Syndication.
